What is the Cost of Rehab in Indiana? Insurance Coverage and Payment Options

Indiana faces a staggering addiction crisis affecting 1.1 million residents aged 12 and older who had substance use disorders in 2021, yet 87% of them did not receive needed specialty treatment (SAMHSA, 2022). Cost barriers represent the primary obstacle preventing Hoosiers from accessing life-saving care, with about half of adults with opioid use disorder citing cost or lack of insurance as reasons for not seeking help (AJPH, 2022). The economic impact reaches over $4 billion annually in healthcare costs, lost productivity, criminal justice expenses, and other impacts across Indiana (Indiana University, 2018).

Multiple insurance options provide coverage for addiction treatment throughout Indiana, with 87.6% of substance use treatment facilities accepting Medicaid insurance as of 2022 (SAMHSA, 2023). The Healthy Indiana Plan (HIP), Indiana’s Medicaid expansion program, enrolled approximately 700,000 residents by 2023 and covers comprehensive addiction services including outpatient therapy, residential treatment, and all FDA-approved medications for opioid use disorder (Indiana Capital Chronicle, 2025). Major private insurers including Anthem Blue Cross and Blue Shield, CareSource, Ambetter, UnitedHealthcare, and Cigna all provide substance use disorder coverage as an essential health benefit, with federal parity laws requiring treatment coverage comparable to other medical conditions (HHS, 2014).

Financial assistance programs and payment alternatives help bridge coverage gaps for Indiana residents seeking treatment. State programs funded by $918 million from national opioid settlements support expanded treatment access, while Federal State Opioid Response grants enable thousands of additional patients to receive medication-assisted treatment outside traditional insurance (WFYI, 2023). Recovery Works provides state-funded addiction treatment for justice-involved individuals lacking insurance, and Federally Qualified Health Centers offer sliding-fee addiction services based on income (Indiana DMHA, 2023). Every dollar invested in addiction treatment generates an estimated $4-$7 in savings through reduced crime, incarceration, and healthcare expenditures (NIDA, 2018).

What Does Rehab Cost in Indiana Without Insurance?

Outpatient therapy sessions typically cost $100-300 per session without insurance coverage in Indiana, while intensive outpatient programs range from $3,000-10,000 for complete treatment cycles. Residential treatment facilities charge $15,000-50,000 for 30-day programs, and medical detoxification services cost approximately $1,000-3,000 depending on the facility and level of medical supervision required. These costs represent significant financial barriers, as affordability is cited by about half of adults with opioid use disorder who felt they needed treatment but did not receive it (AJPH, 2022).

Hospital emergency department visits for overdoses exceed $10,000 per admission in Indiana, creating substantial costs for both patients and the healthcare system (Indiana Hospital Association, 2020). The broader economic impact reaches $4 billion annually from opioid misuse across Indiana, encompassing healthcare expenses, lost productivity, criminal justice costs, and other societal impacts (Indiana University, 2018). Treatment represents a cost-effective intervention, with every $1 spent on addiction treatment saving $4-7 in related expenses through reduced crime, incarceration, and emergency healthcare utilization (NIDA, 2018).

Cash-paying patients face additional challenges accessing medication-assisted treatment, as fewer than 10% of people with opioid use disorder nationwide receive medications like buprenorphine or methadone (NIDA, 2020). Approximately 955,000 Hoosiers who needed substance use treatment did not receive it in 2021, representing 87% of Indiana residents with substance use disorders who had unmet treatment needs (SAMHSA, 2022). The financial burden particularly affects those without insurance, as about 1.1 million Indiana residents age 12 and older had substance use disorders in 2021, yet the vast majority lacked access to specialty treatment (SAMHSA, 2022).

How Does Indiana Medicaid Cover Addiction Treatment?

Indiana’s Healthy Indiana Plan (HIP) provides comprehensive addiction treatment coverage for approximately 700,000 enrollees, representing a massive expansion from initial projections of around 200,000 members (Indiana Capital Chronicle, 2025). The program covers the complete continuum of care, including detoxification services, outpatient counseling, residential treatment, medication-assisted treatment, and recovery support services. Medically frail enrollees, including those with serious substance use disorders, receive enhanced benefits without cost-sharing requirements, ensuring financial barriers don’t prevent access to critical care (Indiana Medicaid, 2023).

Provider participation in Medicaid reaches exceptional levels in Indiana, with 87.6% of substance use treatment facilities accepting Medicaid insurance compared to the national average of 74% (SAMHSA, 2023). This acceptance rate increased by 1.9 percentage points from 2021 to 2022, reflecting growing provider engagement with the Medicaid program. The state’s 421 substance use disorder treatment facilities create a robust network of care options for HIP members seeking addiction treatment services (SAMHSA, 2023).

Federal approval of Indiana’s 2018 SUD waiver transformed treatment accessibility by enabling Medicaid coverage of residential addiction treatment in larger facilities previously excluded from reimbursement (CMS, 2018). The waiver eliminated prior authorization requirements for critical medications including buprenorphine, methadone, and naltrexone, removing administrative barriers that often delayed treatment initiation. Despite these coverage improvements, only 5% of Indiana Medicaid enrollees diagnosed with opioid use disorder received any addiction treatment according to recent claims analysis, highlighting significant gaps between coverage availability and actual service utilization (Health Equity, 2023).

What Treatment Services Does HIP Cover for Addiction?

The Healthy Indiana Plan provides comprehensive addiction treatment coverage including outpatient counseling services, residential treatment programs, and all FDA-approved medications for opioid use disorder such as methadone, buprenorphine, and naltrexone. Indiana Medicaid covers all FDA-approved medications for opioid use disorder and has removed prior authorization requirements for these treatments to reduce barriers (Indiana Medicaid, 2020). Peer recovery coaching and recovery housing support services are also covered benefits, funded through innovative Medicaid waiver programs that help improve long-term outcomes for individuals in treatment (Indiana FSSA, 2019).

Naloxone coverage represents a critical harm reduction benefit, with Indiana Medicaid and many private plans now covering naloxone with no or minimal copay to increase availability for those at risk of overdose (CDC, 2021). The state has distributed tens of thousands of free naloxone kits to Hoosiers in recent years as part of overdose prevention strategies (IDOH, 2023). HIP’s benefit package covers the full continuum of addiction treatment, from outpatient therapy and inpatient rehabilitation stays to medications for addiction treatment and recovery support services (Indiana Medicaid, 2023).

Medically frail enrollees with serious substance use disorders receive enhanced protections under HIP, as they are exempt from cost-sharing requirements and receive expanded benefits (Indiana Medicaid, 2023). In fiscal year 2022, thousands of Medicaid members accessed critical services, with over 15,000 receiving outpatient addiction counseling and several thousand receiving residential treatment through covered benefits (Indiana FSSA, 2023). This comprehensive coverage addresses the significant treatment gap, as approximately 955,000 Hoosiers who needed substance use treatment did not receive it in 2021, representing roughly 87% of Indiana residents with substance use disorders having unmet treatment needs (SAMHSA, 2022).

Can You Get Rehab Coverage Through Private Insurance in Indiana?

Federal parity laws mandate that private insurance companies cover substance use disorder treatment at the same level as medical and surgical conditions, eliminating discriminatory practices like higher copays or stricter authorization requirements for addiction care. All ACA marketplace plans must include SUD treatment as an essential health benefit, ensuring comprehensive coverage regardless of the insurer (HHS, 2014). Major insurers like Anthem, Cigna, and Aetna eliminated prior authorization requirements for buprenorphine and other opioid addiction medications by 2017, removing critical barriers to treatment access (Bloomberg, 2017).

Anthem Blue Cross Blue Shield dominates Indiana’s private insurance market with 38-42% market share and serves dual roles as both a private insurer and Medicaid managed care entity through the Healthy Indiana Plan (IBJ, 2010). CareSource operates one of the nation’s largest Medicaid managed care programs while maintaining a strong marketplace presence, capturing 86% of new Indiana marketplace enrollees during a 2021 special enrollment period (CareSource, 2021). UnitedHealthcare expanded into Indiana’s individual marketplace in 2024 and participates in multiple Medicaid programs, while Cigna achieved a 25% reduction in opioid use among covered members by 2018 through enhanced prescription safeguards and treatment access initiatives (Cigna, 2018).

Approximately 67% of Indiana’s substance use disorder treatment facilities accept private insurance, with 94% accepting cash payments as alternative payment options (SAMHSA, 2021). Private insurance’s role in funding SUD treatment has expanded significantly since parity implementation, with the share of national treatment expenditures paid by private insurers increasing from 19% in 2010 to 28% by 2018 (SAMHSA, 2020). Research demonstrates that full enforcement of mental health and SUD parity requirements produces only a 1% premium increase while dramatically expanding access to necessary addiction treatment services (SAMHSA, 2016).

Which Insurance Plans Provide the Best Addiction Treatment Coverage?

Anthem Blue Cross and Blue Shield dominates Indiana’s insurance landscape, covering 38-42% of Hoosiers with private insurance while also serving as a major Medicaid managed care entity through the Healthy Indiana Plan (Anthem Blue Cross and Blue Shield, 2023). CareSource demonstrated remarkable market penetration during 2021’s special enrollment period, capturing 86% of new Indiana Marketplace enrollees and leveraging its nonprofit status to administer one of the nation’s largest Medicaid managed care programs serving over 2 million members across five states (CareSource, 2021). UnitedHealthcare expanded its Indiana presence in 2024 by entering the individual marketplace while continuing to participate in Medicaid programs including Hoosier Care Connect and Pathways for Aging (FSSA, 2023).

Major insurers eliminated critical treatment barriers by 2017 when Anthem, Cigna, and Aetna dropped prior authorization requirements for buprenorphine and other medication treatments for opioid addiction (Bloomberg, 2017). Cigna’s proactive approach included removing prior authorization for addiction medications and implementing prescription safeguards that achieved a 25% reduction in opioid use among covered members by 2018 (Cigna, 2018). A Cigna pilot program from 2018-2021 expanded medication-assisted treatment access in select markets, resulting in an 18% reduction in opioid overdose deaths among participating customers (Cigna, 2022).

Indiana Medicaid covers all FDA-approved medications for opioid use disorder including methadone, buprenorphine, and naltrexone without prior authorization requirements, serving the 21% of Medicaid enrollees who have substance use disorders compared to 16% of those with commercial insurance (KFF, 2023). The state’s 2018 SUD waiver enabled Medicaid to cover short-term residential substance abuse treatment and certify new residential providers, while 87.6% of Indiana’s treatment facilities accepted Medicaid insurance in 2022, higher than the national average of 74% (SAMHSA, 2023). Medicaid expansion through the Healthy Indiana Plan has grown to roughly 700,000 enrollees by 2023, far exceeding initial projections of 200,000 and providing enhanced benefits without cost-sharing for medically frail enrollees including those with serious substance use disorders (Indiana Capital Chronicle, 2025).

Does Medicare Pay for Addiction Treatment in Indiana?

Medicare significantly expanded addiction treatment coverage in January 2020 by including methadone treatment at opioid treatment programs for the first time in the program’s history (CMS, 2020). This landmark change addressed a critical gap, as 1.1 million Medicare beneficiaries nationally have opioid use disorder, yet only 18% receive medication-assisted treatment (HHS OIG, 2023). In Indiana, 68% of substance use disorder treatment facilities accept Medicare, providing broader access for seniors and disabled individuals who depend on this federal insurance program (SAMHSA, 2023).

Coverage disparities persist within Medicare’s opioid treatment benefits, particularly affecting certain demographic groups and treatment types. Medicare enrollees without low-income subsidies and some racial and ethnic minorities experience significantly lower rates of buprenorphine coverage compared to other beneficiaries (HHS OIG, 2023). An estimated 52,000 Medicare enrollees experienced opioid overdoses in 2022, demonstrating the urgent need for expanded treatment access among older adults and people with disabilities (HHS OIG, 2023).

The Medicare expansion covers all FDA-approved medications for opioid use disorder, including methadone maintenance at certified opioid treatment programs, buprenorphine prescriptions, and naltrexone injections. Prior to 2020, Medicare’s exclusion of methadone treatment forced many beneficiaries to pay out-of-pocket costs exceeding $6,000 annually or forgo this evidence-based treatment entirely. The coverage now includes counseling services, drug testing, and medical monitoring required for comprehensive opioid addiction treatment at Medicare-certified facilities throughout Indiana.

What Happens if You Lose Medicaid Coverage During Treatment?

The 2023-2024 Medicaid unwinding removed approximately 479,000 Hoosiers from coverage as states resumed eligibility checks after the pandemic (KFF, 2024). This massive disenrollment raised significant concerns about treatment continuity, particularly for individuals receiving medication-assisted treatment for opioid use disorder. Research indicates that Medicaid coverage interruptions increase overdose risks, since continuous insurance coverage proves crucial for maintaining access to buprenorphine, methadone, and other life-saving medications (University of Michigan, 2025). States experiencing the largest Medicaid coverage losses during unwinding witnessed more opioid treatment disruptions, with patients becoming less likely to continue therapy and more likely to pay cash for treatment.

Federal authorities established special enrollment periods allowing individuals losing Medicaid to transition into ACA marketplace plans outside normal enrollment windows. This critical policy intervention helped 125,000 Hoosiers who lost Medicaid coverage successfully transition into marketplace insurance, preventing treatment disruptions for thousands receiving addiction care (KFF, 2024). All marketplace plans must cover substance use disorder treatment as an essential health benefit, ensuring continuity of care for those transitioning from Medicaid (HHS, 2014). The extended enrollment periods proved especially vital given that 21% of Medicaid enrollees have substance use disorders compared to 16% of commercially insured individuals (KFF, 2023).

Coverage gaps during the unwinding period highlighted the vulnerability of addiction treatment access to insurance disruptions. Studies found that individuals with opioid use disorder who maintain continuous health coverage achieve significantly higher treatment retention rates and lower relapse risks than those experiencing insurance gaps (J. Subst. Abuse Treat., 2021). The 87,000 people previously enrolled in treatment facilities that accept Medicaid faced potential barriers, as 87.6% of Indiana’s substance use treatment facilities accepted Medicaid in 2022 compared to lower rates for other payment sources (SAMHSA, 2023). Emergency measures including enhanced outreach and streamlined marketplace enrollment helped preserve treatment continuity during this unprecedented coverage transition period.

How Can You Pay for Rehab Without Insurance in Indiana?

State Opioid Response grants funded addiction treatment for thousands of uninsured Indiana residents, providing medications, counseling, and recovery support services outside traditional insurance systems (SAMHSA, 2023). Federally Qualified Health Centers operate throughout Indiana using sliding-fee scales based on income, extending addiction treatment access to low-income populations regardless of insurance status (HRSA, 2023). The Recovery Works program specifically targets justice-involved individuals without insurance coverage, ensuring people in drug courts or exiting incarceration can access rehabilitation and recovery support services (Indiana DMHA, 2023).

Cash payment and self-pay options remain widely available, with 94% of Indiana treatment facilities accepting direct payment arrangements (SAMHSA, 2021). Treatment centers typically offer payment plans, reduced rates for uninsured patients, and flexible financial arrangements to accommodate varying economic circumstances. Indiana’s network of community health centers provides comprehensive addiction services on income-adjusted fee schedules, supported by federal grants and state funding streams that supplement patient payments.

Indiana’s allocation of $918 million from national opioid settlements represents a significant investment in expanded treatment programs, prevention initiatives, and recovery support infrastructure across communities statewide (WFYI, 2023). These settlement funds specifically target underserved populations and uninsured individuals who previously faced financial barriers to accessing care. Additional state resources include peer recovery coaching programs, mobile crisis response units, and harm reduction services that connect people to treatment regardless of their ability to pay for comprehensive rehabilitation services.

What Free and Low-Cost Treatment Options Exist in Indiana?

Indiana operates 25 opioid treatment programs statewide that provide methadone services on sliding fee scales based on income, ensuring access regardless of insurance status (Pew, 2021). Community health centers throughout the state offer addiction treatment using federally mandated sliding fee structures that can reduce costs to as low as $20 per visit for qualifying individuals (HRSA, 2023). Federally Qualified Health Centers extend these services to uninsured populations, with 87.6% of Indiana’s substance use treatment facilities accepting Medicaid compared to the national average of 74% (SAMHSA, 2023).

Peer recovery coaches now operate in emergency departments and county jails across Indiana, connecting individuals to treatment during critical intervention moments. Recovery hub programs complement these efforts by providing immediate access to services, while syringe exchange programs in multiple counties serve dual harm reduction and treatment connection functions (IDOH, 2022). The state’s Recovery Works program specifically targets justice-involved individuals without insurance, ensuring continuity of care for people transitioning from incarceration to community-based treatment (Indiana DMHA, 2023).

Indiana’s 2-1-1 help line and Be Well crisis line together field thousands of calls annually, providing treatment connections regardless of insurance coverage or ability to pay (FSSA, 2025). These services prove essential given that 955,000 Hoosiers who needed substance use treatment did not receive it in 2021, with cost barriers being the primary obstacle for 39% of individuals who recognize their need for care (SAMHSA, 2022). Federal State Opioid Response grants have enabled thousands of additional patients to receive medication-assisted treatment and counseling outside traditional insurance frameworks, while tens of thousands of free naloxone kits have been distributed statewide as an immediate overdose prevention measure (SAMHSA, 2023).

Why Do Treatment Gaps Exist Despite Insurance Coverage?

Despite widespread insurance coverage for substance use disorder treatment, systemic barriers prevent most Hoosiers from accessing care. Only 5% of Indiana Medicaid enrollees with opioid use disorder receive any addiction treatment, while approximately 87% of the 1.1 million Indiana residents with substance use disorders did not receive needed specialty treatment in 2021 (Health Equity, 2023; SAMHSA, 2022). This treatment gap persists even though 87.6% of Indiana’s substance use treatment facilities accept Medicaid insurance, indicating that coverage alone cannot overcome access barriers (SAMHSA, 2023).

Gender and racial disparities create additional obstacles to treatment access within insured populations. Male Medicaid enrollees with opioid use disorder are 37% more likely to receive detox services and 28% more likely to receive medication-assisted treatment than female enrollees, despite women comprising 56% of Indiana Medicaid enrollees with OUD (Health Equity, 2023). Racial disparities compound these barriers, with only 4 in 10 Black Medicaid enrollees with opioid use disorder receiving medication treatment compared to nearly 7 in 10 White enrollees with the same condition (KFF, 2024).

Treatment retention challenges further limit the effectiveness of available services, with less than half of patients remaining in medication treatment after 6 months nationwide (NIDA, 2020). Stigma, provider capacity limitations, transportation barriers, and lack of culturally competent care contribute to both initial access problems and premature treatment discontinuation. These structural barriers explain why 955,000 Hoosiers who needed substance use treatment did not receive it in 2021, despite Indiana’s expanded Medicaid coverage and federal parity requirements mandating equal treatment coverage (SAMHSA, 2022).

Rediscover Life at The Grove Estate

Get the compassionate mental health support you deserve. We're here to help you reclaim joy, wellness, and a brighter future.

Our Facility

How Does Gender and Race Affect Treatment Access in Indiana?

Women comprise 56% of Indiana Medicaid enrollees with opioid use disorder, yet face significant barriers to accessing medication-assisted treatment compared to their male counterparts (Health Equity, 2023). Male Medicaid enrollees with OUD were 37% more likely to receive detox services and 28% more likely to receive agonist medications like methadone or buprenorphine than female enrollees (Health Equity, 2023). This gender disparity occurs despite women representing the majority of those diagnosed with OUD in Indiana’s Medicaid population, creating substantial gaps in evidence-based treatment access.

Racial disparities reveal distinct patterns in treatment allocation across Indiana’s Medicaid system. White enrollees with OUD were significantly more likely to receive detox and counseling services, while non-White enrollees were more likely to receive agonist medication treatments (Health Equity, 2023). National data reinforces these disparities, showing that only 4 in 10 Black Medicaid enrollees with opioid use disorder received medication treatment compared to nearly 7 in 10 White enrollees with OUD (KFF, 2024). Black, Hispanic, and Asian enrollees, along with teens and young adults, consistently demonstrate lower SUD treatment rates than White enrollees or older adults within Medicaid programs (KFF, 2024).

Systemic barriers contributing to these disparities include provider bias, geographic accessibility challenges, and differential treatment approaches across demographic groups. Indiana has implemented several initiatives to address these inequities, including removing prior authorization requirements for all FDA-approved OUD medications, expanding recovery hub programs with peer recovery coaches, and investing $918 million from national opioid settlements into expanded treatment and prevention programs (WFYI, 2023). The state’s SUD waiver allows Medicaid coverage for residential treatment in larger facilities previously excluded, while “medically frail” enrollees with serious SUD receive enhanced benefits without cost-sharing requirements (Indiana Medicaid, 2023).

What Should You Know About Medication-Assisted Treatment Coverage?

Indiana Medicaid covers all FDA-approved medications for opioid use disorder including methadone, buprenorphine, and naltrexone without prior authorization requirements (Indiana Medicaid, 2020). Medicaid nationally covers roughly half of all buprenorphine prescriptions dispensed for OUD treatment, reflecting its critical role in treatment financing (KFF, 2021). Private insurers in Indiana, including Anthem Blue Cross Blue Shield, Cigna, and CareSource, are required under federal parity laws to cover addiction treatment comparably to other medical conditions and have eliminated prior authorization barriers for medication-assisted treatment by 2017 (Bloomberg, 2017).

Despite comprehensive coverage availability, fewer than 10% of people with opioid use disorder nationwide receive these life-saving medications (NIDA, 2020). In Indiana specifically, only about 5% of Medicaid enrollees diagnosed with opioid use disorder received any addiction treatment according to recent claims analysis (Health Equity, 2023). Significant disparities exist within covered populations, with male Medicaid enrollees being 28% more likely to receive agonist medication like methadone or buprenorphine than female enrollees, and only 4 in 10 Black Medicaid enrollees with OUD receiving medication treatment compared to nearly 7 in 10 White enrollees (Health Equity, 2023).

Coverage expansion through Indiana’s Healthy Indiana Plan has dramatically increased treatment access, with the program growing to roughly 700,000 enrollees by 2023 far above initial projections of 200,000 (Indiana Capital Chronicle, 2025). The state received federal approval in 2018 for an SUD waiver expanding Medicaid coverage of inpatient addiction treatment and residential treatment services previously excluded from coverage (CMS, 2018). About 87.6% of Indiana’s substance use treatment facilities accepted Medicaid insurance in 2022, higher than the national average of 74%, while roughly two-thirds accepted Medicare coverage (SAMHSA, 2023).

How Do You Navigate Insurance Pre-Authorization and Coverage Denials?

Insurance coverage denials for addiction treatment require immediate action through formal appeals processes that leverage federal parity protections. Mental health parity laws mandate that insurers cover substance use disorder treatment comparably to medical conditions, preventing discriminatory higher copays or stricter authorization requirements (GAO, 2019). Major insurers including Anthem, Cigna, and Aetna eliminated prior authorization requirements for buprenorphine and other medication-assisted treatments by 2017, though some barriers may persist for specialized services like residential treatment (Bloomberg, 2017). When denials occur, patients should request written denial reasons, gather supporting documentation from providers, and file appeals within specified timeframes while continuing necessary treatment.

Provider selection significantly impacts insurance authorization success rates and treatment continuity. 87.6% of Indiana’s substance use treatment facilities accept Medicaid insurance, exceeding the national average of 74% and indicating robust provider network participation (SAMHSA, 2023). Healthcare professionals experienced with insurance requirements can navigate pre-authorization processes more effectively, submit comprehensive treatment justifications, and maintain documentation standards that support coverage approvals. Facilities participating in multiple insurance networks often have dedicated staff to handle authorization requests and can provide alternative treatment options when specific services face coverage challenges.

Coverage disruptions during Medicaid eligibility changes create critical treatment access risks that require proactive insurance transitions. Over 125,000 Hoosiers who lost Medicaid coverage successfully transitioned to ACA Marketplace plans through extended special enrollment periods in 2023-2024, preventing treatment interruptions (KFF, 2024). Continuous insurance coverage proves essential for recovery outcomes, as individuals maintaining health coverage show significantly higher treatment retention and lower relapse rates compared to those experiencing coverage gaps. States with the largest Medicaid coverage losses during recent eligibility redeterminations experienced increased opioid treatment disruptions, with patients less likely to continue buprenorphine therapy and more likely to pay cash for essential services (University of Michigan, 2025).

Is Addiction Treatment Cost-Effective for Indiana?

Every dollar invested in addiction treatment generates $4–$7 in savings through reduced crime, incarceration, and healthcare expenditures, making treatment one of the most cost-effective public health interventions available (NIDA, 2018). Medication-assisted treatment delivers particularly strong returns by reducing fatal overdose risk by roughly half compared to no treatment, while people actively engaged in treatment demonstrate significantly higher employment rates and productivity levels (NIH, 2021). The economic case becomes even more compelling when considering that individuals who receive adequate substance use disorder treatment contribute back to the economy through increased workforce participation and reduced reliance on social services (NIDA, 2022).

These treatment investments directly offset Indiana’s staggering $4 billion annual cost from opioid misuse alone—roughly $11 million every day in healthcare expenses, lost productivity, criminal justice costs, and other impacts (Indiana University, 2018). The average hospital cost for a single non-fatal opioid overdose exceeds $10,000 per admission, with much of this burden falling on Medicaid and uninsured care funds (Indiana Hospital Association, 2020). Government and taxpayers shoulder approximately 30% of the economic costs from the opioid epidemic, while the remaining 70% impacts the private sector and individuals through reduced productivity, healthcare premiums, and other indirect costs (NPR, 2019).

The treatment gap represents a massive economic opportunity, with 955,000 Hoosiers who needed substance use treatment not receiving it in 2021—approximately 87% of Indiana residents with substance use disorders had unmet treatment needs (SAMHSA, 2022). Only 5% of Indiana Medicaid enrollees diagnosed with opioid use disorder received any addiction treatment according to recent claims analysis, despite Medicaid serving as the single largest payer for behavioral health services nationwide (Health Equity, 2023). Closing this treatment gap through expanded access could prevent thousands of overdose deaths annually while generating billions in economic savings for Indiana communities, employers, and taxpayers.

How Can You Get Help Finding Affordable Treatment in Indiana?

Indiana’s 2-1-1 helpline connects residents to local addiction treatment resources regardless of insurance status, while the state’s Be Well crisis line provides immediate support for substance use emergencies (FSSA, 2025). The SAMHSA treatment locator helps identify facilities among Indiana’s 421 treatment centers that accept specific insurance types, with 87.6% accepting Medicaid and 68% accepting Medicare coverage (SAMHSA, 2023). Recovery hubs deployed across the state offer peer coaching and direct connections to treatment programs, particularly effective in emergency departments and community settings where people first seek help.

Indiana’s Healthy Indiana Plan covers approximately 700,000 residents with comprehensive addiction treatment benefits, including outpatient therapy, residential rehabilitation, and all FDA-approved medications for opioid use disorder without prior authorization requirements (Indiana Capital Chronicle, 2025). The state’s 2018 Medicaid SUD waiver expanded coverage to include short-term residential treatment and certified new providers under Medicaid, significantly broadening the treatment network (CMS, 2018). Major insurers including Anthem Blue Cross Blue Shield, CareSource, and UnitedHealthcare participate in both Medicaid managed care and marketplace plans, ensuring treatment access across different coverage types.

Federal parity laws require all Indiana insurers to cover addiction treatment equivalent to medical care, while ACA marketplace plans must include substance use disorder treatment as an essential health benefit (HHS, 2014). The state received $918 million from opioid settlements to expand treatment infrastructure and support uninsured individuals through programs like Recovery Works for justice-involved populations (WFYI, 2023). Federally Qualified Health Centers throughout Indiana provide addiction treatment on sliding fee scales supported by grants and Medicaid, extending services to underserved communities where insurance gaps persist (HRSA, 2023).